Welcome!

News Feed Item

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Arteriosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Arteriosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Coronary Arteriosclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Coronary Arteriosclerosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Coronary Arteriosclerosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Pfizer Inc. 31
Clinical Trial Overview of Pfizer Inc. 31
Merck & Co., Inc. 32
Clinical Trial Overview of Merck & Co., Inc. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Cytori Therapeutics, Inc. 34
Clinical Trial Overview of Cytori Therapeutics, Inc. 34
C. H. Boehringer Sohn AG & Co. KG 35
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
MDDX LLC 37
Clinical Trial Overview of MDDX LLC 37
Innovaderm Research Inc. 38
Clinical Trial Overview of Innovaderm Research Inc. 38
CardioVascular BioTherapeutics, Inc. 39
Clinical Trial Overview of CardioVascular BioTherapeutics, Inc. 39
Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Top Institutes / Government 41
National Heart, Lung, and Blood Institute 41
Clinical Trial Overview of National Heart, Lung, and Blood Institute 41
Providence VA Medical Center 42
Clinical Trial Overview of Providence VA Medical Center 42
National Taiwan University Hospital 43
Clinical Trial Overview of National Taiwan University Hospital 43
Seoul National University Hospital 44
Clinical Trial Overview of Seoul National University Hospital 44
Rigshospitalet 45
Clinical Trial Overview of Rigshospitalet 45
University of Ottawa Heart Institute 46
Clinical Trial Overview of University of Ottawa Heart Institute 46
University of California, San Diego 47
Clinical Trial Overview of University of California, San Diego 47
University of Minnesota 48
Clinical Trial Overview of University of Minnesota 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Five Key Clinical Profiles 51
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Coronary Arteriosclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 31
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 32
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytori Therapeutics, Inc., 2014* 34
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 35
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by MDDX LLC, 2014* 37
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014* 38
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioVascular BioTherapeutics, Inc., 2014* 39
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avant Immunotherapeutics, Inc, 2014* 40
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 41
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Providence VA Medical Center, 2014* 42
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 43
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 44
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 45
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 46
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 47
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 48
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50

List of Figures
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 82

Read the full report:
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assis...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Regardless of what business you’re in, it’s increasingly a software-driven business. Consumers’ rising expectations for connected digital and physical experiences are driving what some are calling the "Customer Experience Challenge.” In his session at @DevOpsSummit at 20th Cloud Expo, Marco Morales, Director of Global Solutions at CollabNet, will discuss how organizations are increasingly adopting a discipline of Value Stream Mapping to ensure that the software they are producing is poised to o...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developers ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.